Filing Analysis
Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc. to acquire significant rights related to 'Apitox'. The agreement includes 100% of Korean market rights and various royalty/revenue participation rights in the US and overseas.
🚩 Red Flags
- The company does not acquire the underlying intellectual property ownership of Apitox, only specific rights/royalties.
- Rights are limited to those actually held by FreeT and are subject to legal assignability.
- Jurisdiction is set to the Seoul Central District Court (Republic of Korea), which may complicate legal recourse for a US-based company.
📋 Key Facts
- Entered into Assignment and Transfer Agreement with FreeT Inc. (successor to CNP Roen Co., Ltd.) on August 19, 2026.
- Acquired 100% of rights relating to the Apitox market for Korean medicine clinics in the Republic of Korea.
- Acquired a 25% royalty entitlement on economic proceeds from Apitox development, licensing, or sale in the United States.
- Acquired a 25% revenue participation right on net proceeds from overseas rights agreements.
- Acquired rights to receive quarterly clinical progress and overseas transaction status updates.
- The agreement excludes underlying intellectual property ownership and certain indication-specific/territorial rights not held by FreeT.
- The agreement is governed by the laws of the Republic of Korea.
Apimeds Pharmaceuticals US, Inc. has appointed Dr. Christopher Kim as its new Chief Scientific Officer (CSO), effective August 5, 2026. Dr. Kim will oversee the scientific and regulatory development of the company's APITOX program.
📋 Key Facts
- Dr. Christopher Kim appointed as Chief Scientific Officer (CSO) effective August 5, 2026.
- Role includes leading scientific, clinical, and regulatory development for the APITOX program.
- Focus of role is research and development, clinical strategy, and advancing APITOX toward commercialization.
- Dr. Kim has long-term involvement with the APITOX program.
Apimeds Pharmaceuticals US, Inc. has announced a 1-for-10 reverse stock split effective July 24, 2026. This follows a significant delay from the previously anticipated March 2026 implementation date.
🚩 Red Flags
- Reverse stock split (typically used to boost share price to meet exchange listing requirements).
- Significant delay in execution: The split was originally expected to be effective March 26, 2026, but has been pushed back by nearly four months.
- The company is an 'emerging growth company', often associated with higher volatility and capital needs.
📋 Key Facts
- Reverse stock split ratio is one-for-ten (1-for-10).
- Effective Date: July 24, 2026, at 12:01 a.m. ET.
- The new CUSIP number will be 03771D201.
- Trading on NYSE American LLC under symbol 'APUS' will resume on a split-adjusted basis on July 24, 2026.
- Stockholders approved the split via written consent on December 1, 2025.
Apimeds Pharmaceuticals US, Inc. has appointed Sungjoon Chae as Co-Chief Executive Officer, effective May 4, 2026. Mr. Chae's professional background is in architecture and urban design, which is entirely unrelated to the company's core pharmaceutical business.
🚩 Red Flags
- Extreme misalignment between the new Co-CEO's professional expertise (architecture/real estate) and the company's industry (pharmaceuticals).
- Appointment driven by a stockholder nomination, which may indicate activist pressure or a shift in control.
- Lack of finalized compensation terms at the time of a major executive appointment.
📋 Key Facts
- Sungjoon Chae appointed as Co-CEO effective May 4, 2026.
- Chae was nominated by a stockholder of the Company rather than a board-led search committee.
- Chae's background is in large-scale real estate development and urban regeneration, with a Master of Architecture from Harvard.
- Material terms of Chae's compensation have not yet been determined.
- The filing was signed by the existing CEO, Dr. Vin Menon, who remains in his role as Co-CEO.
Apimeds Pharmaceuticals US entered into a comprehensive settlement and forbearance agreement to resolve a major shareholder dispute and debt defaults. The company faces a potential merger unwind if its 2025 audit is qualified or delayed, and it must execute a 1-for-10 reverse stock split to maintain its NYSE listing.
🚩 Red Flags
- Default on $11,000,000 senior convertible note.
- Mandatory 1-for-10 reverse stock split required for NYSE compliance.
- Potential unwind of the core Merger Agreement based on audit results.
- History of 'purported' board removals and shareholder disputes (Majority Stockholder Dispute).
- NYSE delisting risk and non-compliance with continued listing requirements.
📋 Key Facts
- Entered into a Confidential Settlement and Mutual Release Agreement with Inscobee Inc. and Apimeds Korea on April 24, 2026.
- Lokahi Therapeutics will contribute $4,000,000 in working capital and forgive a $750,000 advance.
- The company entered a Forbearance Agreement with Alto Opportunity Master Fund regarding an $11,000,000 senior convertible note currently in default.
- A mandatory 1-for-10 reverse stock split must be effected by June 30, 2026, as a condition of forbearance.
- The December 2025 merger is subject to an unwind if the 2025 Form 10-K is not filed by April 30, 2026, or if the audit opinion is qualified.
- Complete board turnover is planned, with current directors Kogan, O'Donnell, and Weintraub expected to resign following the 10-K filing.
Apimeds Pharmaceuticals US, Inc. received a notice from NYSE American on April 17, 2026, for failing to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company's common stock has been under a trading halt since April 2, 2026, and will carry a ".LF" designation upon resumption of trading.
🚩 Red Flags
- Failure to file the mandatory Annual Report (Form 10-K) for fiscal year 2025.
- Existing trading halt on the common stock since April 2, 2026, which predates the official notice.
- Audit procedures are taking longer than the standard extension period (Form 12b-25 was filed March 31, 2025).
- Addition of the '.LF' (Late Filing) suffix to the ticker symbol.
📋 Key Facts
- Received NYSE non-compliance notice on April 17, 2026, regarding Section 1007 of the NYSE American Listed Company Manual.
- The Company has an initial six-month cure period (until October 17, 2026) to file the delinquent Form 10-K.
- Trading of APUS common stock has been halted since April 2, 2026.
- The delay is attributed to the finalization of financial statements and the completion of audit procedures by the independent accounting firm.
- The Company expects to file the Form 10-K by April 30, 2026.
Apimeds Pharmaceuticals US, Inc. announced it will miss the 15-day extension period for filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company expects to receive a notice of non-compliance from NYSE American as a result of this delay.
🚩 Red Flags
- Failure to file 10-K within the 15-day extension period provided by Rule 12b-25.
- Anticipated exchange non-compliance notice from NYSE American.
- Extended audit procedures suggest potential complexities or disagreements in financial reporting.
📋 Key Facts
- The company filed a Form 12b-25 on March 31, 2026, but will not meet the 15-day extension deadline.
- The delay is due to ongoing preparation of financial statements and the need for additional time for the independent auditor to complete procedures.
- The company expects a notice from NYSE American regarding non-compliance with continued listing requirements.
- The company aims to file the Form 10-K by April 30, 2026, though no assurance is provided.
The company filed an amendment to a previous 8-K to declare that a 'Stockholder Consent' action by majority stockholders (Inscobee Inc. and Apimeds Korea) to remove the entire Board of Directors and the CEO/CFO is null and void. The company asserts these actions violated a Support Agreement and Delaware law.
🚩 Red Flags
- Extreme corporate governance instability: Attempted 'coup' by majority stockholders to purge the Board and C-suite.
- Legal conflict between the company and its majority shareholders regarding voting rights and contractual obligations.
- High probability of imminent litigation regarding the validity of the Stockholder Consent and the Support Agreement.
📋 Key Facts
- On March 20, 2026, majority stockholders Inscobee Inc. and Apimeds Korea attempted to remove directors Elona Kogan, Jakap Koo, Carol O’Donnell, and Dr. Bennett Weintraub.
- The same action attempted to remove CEO Dr. Vin Menon and CFO Erick Frim.
- The company claims the action used 6,416,365 shares subject to an irrevocable proxy that was not authorized by the proxy holder.
- The company asserts the action violated the 'Anti-Frustration Covenant' and 'Waiver of Consent Rights' in a Support Agreement related to a December 1, 2025, merger with MindWave Innovations Inc.
- The company has declared the attempted removals and subsequent bylaw amendments invalid 'ab initio'.
Apimeds Pharmaceuticals US is facing a hostile attempt by major stockholders Inscobee Inc. and Apimeds Korea to remove its entire board of directors and executive leadership. The company has declared the removal attempt void, citing a breach of a Support Agreement and an irrevocable proxy, and intends to litigate the matter in the Delaware Court of Chancery.
🚩 Red Flags
- Hostile attempt by major shareholders to seize control of the Board and executive management.
- Alleged material breach of a Support Agreement and irrevocable proxy by major stockholders.
- Immediate litigation in the Delaware Court of Chancery regarding corporate control.
- Conflicting claims of authority, with unauthorized parties attempting to enter into business agreements on behalf of the company.
📋 Key Facts
- On March 20, 2026, Inscobee Inc. and Apimeds Korea attempted to remove all four board members and the CEO (Dr. Vin Menon) and CFO (Mr. Erick Frim).
- The removal attempt utilized 6,416,365 shares of common stock.
- The Company claims these shares are subject to an irrevocable proxy granted to the Company under a Support Agreement dated December 1, 2025, related to the MindWave Innovations merger.
- The Company is petitioning the Delaware Court of Chancery under 8 Del. C. § 225 to declare the stockholder consent void.
- The purported new board members have already announced unauthorized business initiatives and MOUs with Assemble Corporation, Hilluck Co. Ltd., and LK Ventures Co., Ltd.
Apimeds Pharmaceuticals US (APUS) underwent a total leadership overhaul as majority stockholders removed the entire board and C-suite via written consent, citing potential wrongdoing related to a merger with MindWave Innovations. The new board, led by CEO Youngjik Cho, has delayed a planned 1-for-10 reverse split and announced a pivot into Korean cosmetics and e-commerce.
🚩 Red Flags
- Hostile removal of the entire board and executive management team.
- Allegations of 'potential wrongdoing' by former management regarding merger transactions.
- Disputed merger with MindWave Innovations involving 'purported ownership of certain digital assets'.
- Unauthorized press releases issued by the merger partner (MindWave) on behalf of the company.
- Sudden pivot in business strategy from pharmaceuticals to cosmetics and photo booths.
- Threatened litigation between the company, its majority stockholders, and former management.
📋 Key Facts
- Majority stockholders (Inscobee and Apimeds Korea, holding >66.6% voting power) removed four directors and the CEO (Dr. Vin Menon) and CFO (Erick Frim) effective March 20, 2026.
- Youngjik Cho was appointed as the new CEO and Chairman of the Board.
- The removal follows an investigation into 'potential wrongdoing' by former directors and officers regarding the merger with MindWave Innovations and the validity of MindWave's digital assets.
- The company delayed a previously announced 1-for-10 reverse stock split originally scheduled for March 26, 2026.
- The new board approved a significant business pivot into Korean cosmetics, e-commerce, and photo booth platforms via non-binding MOUs with Assemble, Hilluck, and LK Ventures.
- MindWave Innovations issued an unauthorized press release challenging the board removal, leading to potential litigation.
Apimeds Pharmaceuticals US, Inc. announced a 1-for-10 reverse stock split of its common stock, effective March 26, 2026. The action was approved by majority stockholders via written consent and is intended to consolidate every ten shares into one.
🚩 Red Flags
- Reverse stock split (1-for-10 ratio) often indicates pressure to maintain exchange listing requirements
- Approval via written consent indicates concentrated voting power among a few stockholders
📋 Key Facts
- Reverse stock split ratio of 1-for-10
- Effective date set for March 26, 2026, at 12:01 a.m. Eastern Time
- Stockholder approval obtained via written consent on December 1, 2025
- Trading on a split-adjusted basis begins at the open of trading on March 26, 2026
- New CUSIP number for common stock will be 03771D201
This 8-K/A filing is an amendment to provide required financial statements and pro forma information following a reverse merger transaction involving MindWave. The filing includes audited and unaudited financial statements for the acquired business entity.
🚩 Red Flags
- Transaction type is a reverse merger, which in micro-cap contexts often carries higher risk profiles regarding shell company history.
📋 Key Facts
- The filing is an Amendment No. 2 to an original 8-K filed on December 2, 2025.
- The purpose of the amendment is to satisfy Item 9.01 requirements regarding a reverse merger transaction.
- Includes unaudited consolidated financial statements as of September 30, 2025 (Exhibit 99.1).
- Includes audited consolidated financial statements for years ended March 31, 2025, and March 31, 2024 (Exhibit 99.2).
- Provides unaudited pro forma combined balance sheets as of September 30, 2025, and combined statements of operations (Exhibit 99.3).
Apimeds Pharmaceuticals US, Inc. announced the removal of Erik Emerson from its Board of Directors by stockholder action effective December 30, 2025.
🚩 Red Flags
- Removal of a director via stockholder written consent can sometimes indicate internal governance disputes or strategic shifts in company direction.
📋 Key Facts
- Erik Emerson was removed from the Company's board of directors via written consent of stockholders.
- The removal was effective as of December 30, 2025.
- The action was taken by a majority of outstanding shares of common stock holding voting power.
- Remaining board members include Elona Kogan, Jakap Koo, Carol O’Donnell, and Dr. Bennett Weintraub, PHD.
Apimeds Pharmaceuticals US, Inc. filed an amendment to its 8-K to correct significant clerical errors in a previously disclosed Merger Agreement and Certificate of Designation. The corrections involve substantial changes to the equity structure resulting from the merger, specifically regarding the issuance of preferred stock.
🚩 Red Flags
- Significant shift in equity ownership structure: The correction reveals the target/merger entities will hold a much higher percentage (90.9%) of the combined company's equity than previously disclosed (61%).
- Massive dilution potential: The issuance of $120.9M in senior convertible notes with an 8% original issue discount represents significant future dilution.
- Correction of material terms: While labeled as 'scrivener's errors,' the changes fundamentally alter the economic outcome for existing shareholders.
📋 Key Facts
- Corrected the Common Stock Cap in the Merger Agreement from 29.9% to 0%.
- Corrected the Acquiror Preferred Stock issuable to existing holders from 61% to 90.9% of total issued and outstanding equity on a fully diluted basis.
- Removed sections (2.05(b) and 2.05(d)) that incorrectly granted the Company rights to appoint directors.
- Corrected the number of 'Series A Convertible Preferred Stock' shares from 7,263,865 to 7,477,017 in the Certificate of Designation.
- Amended a Securities Purchase Agreement (dated Dec 8, 2025) involving $120.9M in senior convertible notes with an institutional investor.
Apimeds Pharmaceuticals US, Inc. announced the resignation of two board members, Dr. Vin Menon and Amir A. Dossal, effective December 5, 2025. The company stated that the resignations were not due to any disagreements regarding operations, policies, or practices.
🚩 Red Flags
- Simultaneous departure of two directors (one being an Independent Director) can sometimes signal internal shifts, though the filing denies disagreement.
📋 Key Facts
- Dr. Vin Menon resigned from the Board of Directors on December 5, 2025.
- Amir A. Dossal (Independent Director) resigned from the Board of Directors on December 5, 2025.
- The company explicitly stated resignations were not due to disagreements with operations, policies, or practices.
Apimeds Pharmaceuticals US, Inc. (APUS) entered into a definitive merger agreement to acquire MindWave Innovations Inc., which will result in the combined entity being controlled by existing holders of MindWave and other investors.
🚩 Red Flags
- Reverse stock split (1-for-10) is explicitly part of the transaction structure/proposals.
- Significant dilution for existing APUS shareholders: Target company stockholders and note holders will control 90.9% of the combined entity.
- Complex capital structure involving Series A Convertible Preferred Stock which could lead to further dilution.
📋 Key Facts
- Merger Agreement signed on December 1, 2025, with MindWave Innovations Inc. as the target company.
- The transaction involves a combination of Apimeds Common Stock and Series A Convertible Preferred Stock as consideration.
- Existing holders of MindWave (the 'Company') will collectively hold 90.9% of the equity capital of the Acquiror on an as-converted basis post-closing.
- A 1-for-10 reverse stock split has been approved via written consent by majority holders to facilitate the transaction and meet exchange requirements.
- The merger involves a 'Merger Sub' (Apimeds Merger Sub, Inc.) which will merge into MindWave Innovations Inc.
Apimeds Pharmaceuticals US, Inc. entered into an amendment to the Executive Employment Agreement for CEO Erik Emerson on November 13, 2025. The amendment increases his annual base salary and clarifies severance terms.
🚩 Red Flags
- Significant severance package (24 months salary) creates a potential liquidity liability in the event of termination without cause.
📋 Key Facts
- Effective Date of Amendment: November 13, 2025
- CEO Erik Emerson's annual base salary increased to $500,000.
- Severance provision: If terminated without cause, Executive receives 24 months of base salary and benefits plus immediate vesting of all unvested equity (subject to release of claims).
- Forfeiture provision: Unvested equity is forfeited if terminated for cause or by the Executive without good reason.
Apimeds Pharmaceuticals US, Inc. amended its bylaws on October 15, 2025, to permit shareholder action by written consent.
📋 Key Facts
- The Board of Directors approved an amendment to the company's bylaws on October 15, 2025.
- The primary change allows shareholders to take action via written consent rather than requiring a formal meeting.
- The amendment is filed as Exhibit 3.1 in this report.
Apimeds Pharmaceuticals US, Inc. filed an 8-K to furnish a press release issued on July 15, 2025. The filing does not contain substantive financial data or material event disclosures within the text provided.
📋 Key Facts
- The company issued a press release on July 15, 2025 (Exhibit 99.1).
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and Item 9.01.
- No specific material news or financial figures were disclosed in the body of this 8-K text.
Apimeds Pharmaceuticals US, Inc. announced the appointment of Erick J. Frim as Chief Financial Officer, replacing Mark Corrao, effective May 30, 2025.
🚩 Red Flags
- The appointment is structured via a consulting agreement rather than a standard full-time executive employment contract, which may indicate cost-cutting or temporary staffing needs.
📋 Key Facts
- Erick J. Frim appointed as CFO on May 30, 2025.
- Mark Corrao is departing the role of CFO.
- Mr. Frim has over 40 years of experience in financial management and previously served at EisnerAmper, LLP and Helio Corporation.
- The company entered into a consulting agreement with Mr. Frim on June 4, 2025.
- Consulting Agreement terms: $2,500/month base fee for 8 hours of service; $250 per hour for additional work; one-year term.
Apimeds Pharmaceuticals US, Inc. amended the terms of three outstanding promissory notes to extend their maturity dates to May 19, 2026. The amendments involve debt owed to Inscobee Inc. and Apimeds Korea (a related party).
🚩 Red Flags
- Related-party transaction: One of the note holders is Apimeds Korea, which appears to be a related entity.
- Debt extension: The company is extending maturity dates on existing debt, suggesting potential liquidity constraints in meeting original repayment terms (specifically the May 19, 2025 deadline for the Inscobee notes).
📋 Key Facts
- Amended three promissory notes: May 20, 2024 Note ($100k), August 19, 2024 Note ($150k), and March 31, 2025 Note ($250k).
- Total principal amount of amended notes is $500,000.
- All notes bear an interest rate of 5% per annum.
- Maturity dates for all three notes have been extended to May 19, 2026.
- The March 2025 Note was originally due upon a December 31, 2026 date or an NYSE American listing.
Apimeds Pharmaceuticals US, Inc. successfully consummated its initial public offering (IPO) of 3,375,000 shares at $4.00 per share, raising approximately $13.5 million in gross proceeds. The filing also details the automatic conversion of outstanding convertible promissory notes into common stock upon the listing.
🚩 Red Flags
- Issuance of warrants (168,750 shares) to underwriters can lead to future dilution.
📋 Key Facts
- IPO pricing: 3,375,000 shares at $4.00 per share.
- Gross proceeds from IPO: $13.5 million (before discounts and expenses).
- Underwriter/Representative: D. Boral Capital LLC.
- Conversion of debt: $772,545 in principal and accrued interest converted into 297,133 shares at a conversion price of $2.60 per share.
- Warrants issued: 168,750 Representative's Warrants issued to D. Boral Capital LLC and designees.
Apimeds Pharmaceuticals US, Inc. amended its bylaws on April 11, 2025, implementing several governance changes that strengthen management control and limit shareholder rights.
🚩 Red Flags
- Governance changes significantly reduce shareholder influence and ability to effect change.
- Elimination of written consent makes it harder for minority shareholders to act between annual meetings.
- Supermajority requirements (66.67%) for director removal and bylaw amendments create high barriers to corporate governance reform.
- Reduced quorum requirement (33 1/3%) may allow a small minority to conduct business if the majority is absent.
📋 Key Facts
- Amended bylaws to establish advanced notice procedures for stockholder proposals and director nominations (Section 5).
- Limited circumstances under which stockholders can convene a special meeting (Section 6(a)).
- Reduced quorum requirement from a majority to 33 1/3% of outstanding shares (Section 8).
- Eliminated the ability for stockholders to act by written consent (Section 13).
- Set Board size between one and seven directors (Section 15).
- Required a 66.67% supermajority vote to remove directors 'for cause' only (Section 19(a)).
- Raised the threshold for stockholders to amend or repeal bylaws to a 66.67% supermajority (Section 20).
- Added a forum selection clause requiring litigation against the Company to be held in Delaware (Section 47).